Skip to main content

Transitioning to intravitreal aflibercept following a previous treat-and-extend dosing regimen in neovascular age-related macular degeneration: 24-month results.

Publication ,  Journal Article
Homer, N; Grewal, DS; Mirza, RG; Lyon, AT; Gill, MK
Published in: Eye (Lond)
September 2015

PURPOSE: To evaluate frequency of injections, visual and anatomical outcomes of neovascular age-related macular degeneration (nAMD) patients transitioned to intravitreal aflibercept after failure to extend treatment interval beyond 8 weeks with prior intravitreal bevacizumab or ranibizumab. METHODS: Retrospective review of patients with nAMD switched to aflibercept following ≥ 6 prior intravitreal ranibizumab or bevacizumab injections at 4-8-week intervals. Three monthly aflibercept injections were given followed by a treat-and-extend dosing regimen. RESULTS: Twenty-one eyes of 18 patients who had received a mean of 23.8 ± 18.8 (mean ± SD; range 6-62) prior ranibizumab or bevacizumab injections were included. Over a mean follow-up of 24 months after the transition, 9.2 ± 2.9 (range 4-21) aflibercept injections were required. Interval between aflibercept injections increased to 57.3 days (range 35-133 days), as compared with 37 ± 6.1 days (range 29-54 days) with the prior agents (P = 0.01). Mean best-corrected visual acuity was preserved (0.42 ± 0.31 vs 0.42 ± 0.23 logMAR; P = 0.2). Mean OCT central subfoveal thickness (292.1 ± 83.2 μm to 283.6 ± 78.6 μm; P = 0.4) and mean macular volume (7.9 ± 0.95 mm(3) to 7.67 ± 0.94 mm(3); P = 0.16) remained stable. CONCLUSION: Patients requiring treatment more frequently than every 8 weeks with ranibizumab and bevacizumab were transitioned to > 8-week treatment interval with aflibercept while maintaining the anatomic and visual gains.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Eye (Lond)

DOI

EISSN

1476-5454

Publication Date

September 2015

Volume

29

Issue

9

Start / End Page

1152 / 1155

Location

England

Related Subject Headings

  • Wet Macular Degeneration
  • Visual Acuity
  • Tomography, Optical Coherence
  • Retrospective Studies
  • Recombinant Fusion Proteins
  • Receptors, Vascular Endothelial Growth Factor
  • Ranibizumab
  • Ophthalmology & Optometry
  • Neovascularization, Pathologic
  • Middle Aged
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Homer, N., Grewal, D. S., Mirza, R. G., Lyon, A. T., & Gill, M. K. (2015). Transitioning to intravitreal aflibercept following a previous treat-and-extend dosing regimen in neovascular age-related macular degeneration: 24-month results. Eye (Lond), 29(9), 1152–1155. https://doi.org/10.1038/eye.2015.87
Homer, N., D. S. Grewal, R. G. Mirza, A. T. Lyon, and M. K. Gill. “Transitioning to intravitreal aflibercept following a previous treat-and-extend dosing regimen in neovascular age-related macular degeneration: 24-month results.Eye (Lond) 29, no. 9 (September 2015): 1152–55. https://doi.org/10.1038/eye.2015.87.
Homer, N., et al. “Transitioning to intravitreal aflibercept following a previous treat-and-extend dosing regimen in neovascular age-related macular degeneration: 24-month results.Eye (Lond), vol. 29, no. 9, Sept. 2015, pp. 1152–55. Pubmed, doi:10.1038/eye.2015.87.

Published In

Eye (Lond)

DOI

EISSN

1476-5454

Publication Date

September 2015

Volume

29

Issue

9

Start / End Page

1152 / 1155

Location

England

Related Subject Headings

  • Wet Macular Degeneration
  • Visual Acuity
  • Tomography, Optical Coherence
  • Retrospective Studies
  • Recombinant Fusion Proteins
  • Receptors, Vascular Endothelial Growth Factor
  • Ranibizumab
  • Ophthalmology & Optometry
  • Neovascularization, Pathologic
  • Middle Aged